JEFFREY J MOLLDREM to Hematopoietic Stem Cell Transplantation
This is a "connection" page, showing publications JEFFREY J MOLLDREM has written about Hematopoietic Stem Cell Transplantation.
Connection Strength
1.091
-
Multi-faceted role of LRP1 in the immune system. Front Immunol. 2023; 14:1166189.
Score: 0.237
-
A GVHD kill switch helps immune reconstitution. Blood. 2014 Jun 19; 123(25):3849-50.
Score: 0.129
-
Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation. Cancer Treat Res. 2009; 144:187-208.
Score: 0.088
-
Vaccinating transplant recipients. Nat Med. 2005 Nov; 11(11):1162-3.
Score: 0.071
-
Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med. 2022 11 16; 14(671):eabo3445.
Score: 0.058
-
Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell. 2022 09 29; 185(20):3705-3719.e14.
Score: 0.057
-
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.
Score: 0.045
-
Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. Blood Adv. 2018 08 28; 2(16):2052-2062.
Score: 0.043
-
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
Score: 0.034
-
Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1174-81.
Score: 0.028
-
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011 Nov 24; 118(22):5957-64.
Score: 0.027
-
Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS One. 2011; 6(8):e23217.
Score: 0.026
-
Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol. 2011 Feb; 4(1):37-50.
Score: 0.026
-
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant. 2010 Jun; 16(6):709-28.
Score: 0.024
-
Immunotherapy of AML. Cancer Treat Res. 2010; 145:237-55.
Score: 0.024
-
Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe. 2024 Sep 11; 32(9):1621-1636.e6.
Score: 0.016
-
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9.
Score: 0.015
-
Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol. 2002 Nov; 9(6):503-8.
Score: 0.014
-
Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood. 2002 Nov 15; 100(10):3690-7.
Score: 0.014
-
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2001 May; 27 Suppl 2:S13-22.
Score: 0.013
-
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7.
Score: 0.013
-
Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2000 Dec; 26(12):1343-5.
Score: 0.013
-
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant. 2000 Jun; 25(11):1137-40.
Score: 0.012
-
Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am. 1999 Oct; 13(5):1041-57, vii-viii.
Score: 0.012
-
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.
Score: 0.011
-
Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy. 2018 08; 20(8):1089-1101.
Score: 0.011
-
Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014 Jan; 16(1):90-100.
Score: 0.008
-
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013 Jan 01; 19(1):247-57.
Score: 0.007
-
Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. Blood. 2011 Aug 25; 118(8):2159-69.
Score: 0.007
-
In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May; 47(5):837-42.
Score: 0.005
-
Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy. 2006; 8(2):149-57.
Score: 0.004